Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | EBP | Q15125 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576461 | 0.91 | EBP (0.62) | KDM4EHRH3EBPSIGMAR1CYP1A2 | |
| SCHEMBL12865043 | 0.83 | KDM4E (0.60) | KDM4EHRH3EBPSIGMAR1CYP1A2 | |
| SCHEMBL491657 | 0.82 | KDM4E (0.55) | KDM4EHRH3 | |
| SCHEMBL3445367 | 0.81 | KDM4E (0.68) | KDM4EHRH3EBPSIGMAR1 | |
| SCHEMBL1283881 | 0.81 | KDM4E (0.58) | KDM4EHRH3EBPSIGMAR1CYP1A2 | |
| SCHEMBL10894213 | 0.81 | KDM4E (0.58) | KDM4EHRH3EBPSIGMAR1 | |
| SCHEMBL6676718 | 0.81 | LTA4H (0.62) | KDM4ECYP1A2LTA4HCYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL10425852 | 0.80 | KDM4E (0.57) | KDM4EHRH3EBPSIGMAR1 | |
| SCHEMBL9706125 | 0.80 | EBP (0.72) | HRH3EBPSIGMAR1CYP1A2LTA4H | |
| SCHEMBL491870 | 0.80 | HRH3 (0.56) | KDM4EHRH3EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2010075197-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KDM4E 891/4885HRH3 2899/4885EBP 4513/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KDM4E 1393/4885HRH3 3666/4885EBP 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.